An important consideration is that TPTD has been approved for two years for osteoporosis [75], which renders a time deadlock in the management of patients with HPP, because it is expected that ALPL expression will decrease after TPTD discontinuation, even in patients having initially responded to this treatment. The gene discussed is ALPL; the disease is osteoporosis.